Is BPAX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,502 people get BPAX articles and Market Currents by email alert.

Get email alerts on BPAX »

HEADLINES:

BioSante Pharmaceuticals, Inc. Reports First Quarter Financial Results

Business Wire (May 10, 2013)
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Special Meetings of Stockholders to Consider Proposed Merger

Business Wire (May 8, 2013)
Huge Potential But Tough Entry For Female Sexual Dysfunction Drugs
Brian L. Wilson • Tue, May 7 • 5 Comments
BioSante Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc. Announce New Merger Agreement

Business Wire (Apr 12, 2013)
Reviving The Blockbuster Potential Of LibiGel For BioSante And Antares Pharma
Ali Yasar • Mon, Apr 8 • 17 Comments
Antares: A Compelling Long-Term Investment
Alexander Maxwell • Thu, Mar 21 • 17 Comments
BioSante Pharmaceuticals, Inc. Sends Letter Urging Stockholders to Vote “FOR” Proposed Merger with ANI Pharmaceuticals, Inc.

Business Wire (Mar 19, 2013)
BioSante Pharmaceuticals Announces Adjournment of Its Stockholders Meeting Until April 12, 2013

Business Wire (Mar 15, 2013)
Glass, Lewis & Co., LLC Recommends Vote “FOR” BioSante/ANI Merger

Business Wire (Mar 4, 2013)
BioSante Pharmaceuticals Provides Merger Update and Reports 2012 Financial Results

Business Wire (Mar 1, 2013)
Leading Independent Proxy Advisory Firm ISS Joins Egan-Jones in Recommending “FOR” BioSante/ANI Merger

Business Wire (Feb 26, 2013)
Following Crashing Biotechs - 5 Bargains To Consider
Craig Keolanui • Tue, Feb 26 • 5 Comments
Egan-Jones Proxy Services Recommends Stockholders Vote “FOR” BioSante and ANI Merger

Business Wire (Feb 19, 2013)
4 Speculative Biotech Stocks To Consider
BuySellShort • Thu, Jan 31 • 28 Comments
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Special Meetings of Stockholders to Consider Proposed Merger

Business Wire (Jan 22, 2013)
Celsion: The Heat Is On
James Stocklasar Thomas Jr. • Wed, Jan 2 • 21 Comments
5 Stocks Ready To Swing Up For A Diversified Portfolio
Vash Patel • Mon, Dec 24, 2012 • 11 Comments
Palatin Investors Prepared For The Long Haul With Another FSD Drug
Brian L. Wilson • Wed, Nov 14, 2012 • 1 Comment
BioSante Pharmaceuticals Reports Third Quarter Financial Results and Merger Update

Business Wire (Nov 8, 2012)
Multiple Catalysts Ahead For Depomed
Chimera Research Group • Wed, Oct 17, 2012 • 3 Comments

To learn more about Seeking Alpha Pro, click here.

BioSante's Reverse Split Equals Shareholder Dilution
James Stocklasar Thomas Jr. • Fri, Jun 1, 2012 • 53 Comments
What BioSante's Balance Sheet Says About Future R&D
Debra Fiakas • Thu, Mar 1, 2012 • 19 Comments
Biosante Pharmaceuticals: Don't Get Suckered In By The Momentum
GuruFundPicks • Tue, Feb 28, 2012 • 6 Comments
BioSante: LibiGel Lives On, FDA Word On Bio-T-Gel May Come At Any Time
Kinetic Investments • Thu, Feb 9, 2012 • 7 Comments
BioSante Has Potential To Double Soon
Kinetic Investments • Mon, Feb 6, 2012 • 48 Comments
Will Biosante's Libigel Make A Comeback?
James Stocklasar Thomas Jr. • Wed, Feb 1, 2012 • 8 Comments
With Libigel A Failure, Where Will Biosante Bottom Out?
GuruFundPicks • Wed, Dec 14, 2011 • 4 Comments
BioSante: Study Generates Confidence For Future Treatment
Len Zehr • Wed, Sep 14, 2011 • 1 Comment
BioSante: A Serendipitous Moment?
James Stocklasar Thomas Jr. • Fri, Jul 22, 2011 • 28 Comments
BioSante Pharmaceuticals Poised for Continued Success
Mike Williams • Thu, Jul 21, 2011 • 11 Comments
With Cancer Vaccines in Play, Will Investors Continue to Buy-In?
M. E. Garza • Wed, Jun 8, 2011 • 4 Comments
Why BioSante Expects a Positive Review of Drug for Female Sexual Disorder
Kaushik Paul • Tue, May 10, 2011 • 5 Comments
Biosante Pharma Up After FDA Announces Review of Testosterone Gel
M. E. Garza • Wed, Apr 13, 2011 • 8 Comments
BioSante's Potential Blockbuster Treatment
Len Zehr • Thu, Mar 31, 2011 • 20 Comments
Biosante: Key Catalysts Should Renew Investor Interest
Sheff Station • Thu, Sep 30, 2010 • 7 Comments
BioSante CEO Pleased With LibiGel Progress
M. E. Garza • Mon, Feb 22, 2010 • 4 Comments
BioSante Pharma's LibiGel: Big Upside Potential
Mike Havrilla • Sun, Sep 27, 2009 • 5 Comments
BioSante: Key Support Is Back
Mike Havrilla • Fri, Nov 14, 2008 • 1 Comment
BioSante Pharma Reaquires Elestrin
Mike Havrilla • Mon, Oct 6, 2008
BioSante Pharma Announces Its Re-Acquisition of Elestrin
Mike Havrilla • Sun, Aug 10, 2008

Huge Potential But Tough Entry For Female Sexual Dysfunction Drugs
Brian L. Wilson • Tue, May 7 • 5 Comments
Reviving The Blockbuster Potential Of LibiGel For BioSante And Antares Pharma
Ali Yasar • Mon, Apr 8 • 17 Comments
Antares: A Compelling Long-Term Investment
Alexander Maxwell • Thu, Mar 21 • 17 Comments
Following Crashing Biotechs - 5 Bargains To Consider
Craig Keolanui • Tue, Feb 26 • 5 Comments
4 Speculative Biotech Stocks To Consider
BuySellShort • Thu, Jan 31 • 28 Comments
Celsion: The Heat Is On
James Stocklasar Thomas Jr. • Wed, Jan 2 • 21 Comments
5 Stocks Ready To Swing Up For A Diversified Portfolio
Vash Patel • Mon, Dec 24, 2012 • 11 Comments
Palatin Investors Prepared For The Long Haul With Another FSD Drug
Brian L. Wilson • Wed, Nov 14, 2012 • 1 Comment
Multiple Catalysts Ahead For Depomed
Chimera Research Group • Wed, Oct 17, 2012 • 3 Comments
3 Ways To Trade Biotechnology Stocks
BubbleBustInvesting • Thu, Sep 20, 2012 • 3 Comments
Under Construction Rehash: Buy Acadia And Astex
James Stocklasar Thomas Jr. • Thu, Sep 20, 2012 • 24 Comments
3 Vaccine Companies With Upcoming Catalysts - Part II
Markus Aarnio • Wed, Sep 12, 2012 • 2 Comments
Targacept Might Be One Company To Stay Away From - For Now
Scott Matusow • Tue, Sep 11, 2012 • 11 Comments
5 BioPharmas To Watch For Wednesday, September 5
Scott Matusow • Wed, Sep 5, 2012 • 15 Comments
Going Into Monday Zalicus' S-3 Surprise
James Stocklasar Thomas Jr. • Mon, Aug 27, 2012 • 30 Comments
5 Pharmaceutical Companies With Phase III Clinical Study Catalysts This Year - Part IV
Markus Aarnio • Mon, Aug 20, 2012 • 6 Comments
Bear Raids And Tree Shaking In Biotechnology And Drugs
Joe Springer • Tue, Aug 7, 2012 • 13 Comments
Strategies You Need To Know To Invest In Speculative Biotech
Michael J. Ray • Mon, Jul 9, 2012 • 58 Comments
10 Verifiable Reasons Why Antares Is An Excellent Investment
James Stocklasar Thomas Jr. • Thu, Jul 5, 2012 • 44 Comments
What This News Means For Healthcare Stocks
Timeless Wealth • Tue, Jun 19, 2012

There are no Transcripts on BPAX.

BioSante Pharmaceuticals, Inc. Reports First Quarter Financial Results

Business Wire (May 10, 2013)
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Special Meetings of Stockholders to Consider Proposed Merger

Business Wire (May 8, 2013)
BioSante Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc. Announce New Merger Agreement

Business Wire (Apr 12, 2013)
BioSante Pharmaceuticals, Inc. Sends Letter Urging Stockholders to Vote “FOR” Proposed Merger with ANI Pharmaceuticals, Inc.

Business Wire (Mar 19, 2013)
BioSante Pharmaceuticals Announces Adjournment of Its Stockholders Meeting Until April 12, 2013

Business Wire (Mar 15, 2013)
Glass, Lewis & Co., LLC Recommends Vote “FOR” BioSante/ANI Merger

Business Wire (Mar 4, 2013)
BioSante Pharmaceuticals Provides Merger Update and Reports 2012 Financial Results

Business Wire (Mar 1, 2013)
Leading Independent Proxy Advisory Firm ISS Joins Egan-Jones in Recommending “FOR” BioSante/ANI Merger

Business Wire (Feb 26, 2013)
Egan-Jones Proxy Services Recommends Stockholders Vote “FOR” BioSante and ANI Merger

Business Wire (Feb 19, 2013)
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Special Meetings of Stockholders to Consider Proposed Merger

Business Wire (Jan 22, 2013)
BioSante Pharmaceuticals Reports Third Quarter Financial Results and Merger Update

Business Wire (Nov 8, 2012)
BioSante Pharmaceuticals, Inc. to Present at BIO Investor Forum

Business Wire (Oct 8, 2012)
Stocks to Watch: Stocks to Watch Friday: Morgan Stanley

at MarketWatch.com (Oct 4, 2012)
Movers & Shakers: Thursday’s biggest gaining and declining stocks

at MarketWatch.com (Oct 4, 2012)
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Merger Agreement

Business Wire (Oct 4, 2012)
BioSante Pharmaceuticals Announces Positive LibiGel® Phase III Safety Data Review and Decision to Conclude the Safety Study

Business Wire (Sep 4, 2012)
BioSante Pharmaceuticals, Inc. to Present at Stifel Nicolaus Healthcare Conference and Rodman & Renshaw Global Investment Conference

Business Wire (Aug 30, 2012)
BioSante Pharmaceuticals Closes $3,475,000 Registered Direct Offering

Business Wire (Aug 20, 2012)
BioSante Pharmaceuticals to Raise $3,475,000 in Registered Direct Offering

Business Wire (Aug 17, 2012)
BioSante Pharmaceuticals Reports Second Quarter Financial Results and Pipeline Update

Business Wire (Aug 1, 2012)

BPAX vs. ETF Alternatives

Company Description

We are a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. Our primary products are gel formulations of testosterone and estradiol. We also are engaged in the development of our proprietary calcium... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, February 4, 3:48 PM Biosante Pharmaceuticals (BPAX) slips today after disclosing in a regulatory filing that it's sold all of its assets related to its GVAX cancer vaccine portfolio to Aduro BioTech, a clinical-stage immunotherapy company, for a $1M up front cash payment plus the potential for future royalty, milestone and sublicense payments. 1 Comment [Healthcare, On the Move]
Thursday, October 4, 2012, 12:45 PM Midday top 10 gainers: VRNG +22%. ELMD +20%. IFNY +18%. JKS +17%. BSI +17%. CHC +16%. EFUT +14%. ARQL +14%. GNK +12%. NIHD +13%.
Top 10 Losers: NUVA -33%. INFA -26%. SRPT -16%. TNGN -15%. HMSY -14%. PBM -12%. DAEG -11%. ISCA -10%. QLIK -9%. BPAX -9%. Comment! [On the Move]
Thursday, October 4, 2012, 9:06 AM BioSante Pharmaceuticals (BPAX) enters a merger deal with ANI Pharmaceuticals in an all-stock deal with BPAX as the surviving company. Former BPAX shareholders will own ~47%. Shares halted. 1 Comment [Healthcare, M&A]
Tuesday, September 4, 2012, 9:54 AM BioSante (BPAX) +7.8% after saying that its LibiGel testosterone gel for menopausal women performed well in a Phase III trial to determine the drug's safety vis a vis cardiovascular problems and breast cancer. As a result, BioSante is ending the study. The firm is now continuing the protocol development of two new Phase III efficacy trials for LibiGel. (PR) Comment! [Healthcare, On the Move]
Tuesday, September 4, 2012, 9:10 AM Premarket gainers: MRX +38%. STEM +20%. HEK +17%. VRX +13%. QCOR +9%. NTWK +9%. BPAX +7%. NAVB +5%. VRNG +5%.
Losers: MNKD -12%. 1 Comment [On the Move]
Tuesday, June 5, 2012, 11:45 AM BioSante (BPAX) +22% on heavy volume after effecting a reverse stock split on Friday that enabled the company to keep its Nasdaq listing. CEO Stephen Simes is due to tomorrow provide an update on the Phase III trials of BioSante's LibiGel testosterone gel and a review of results involving its GVAX cancer immunotherapies. 1 Comment [On the Move, Healthcare]
Wednesday, May 30, 2012, 10:09 AM BioSante Pharmaceuticals (BPAX) -7.4% to $0.46, although it's not clear what's pulling shares lower. The stock hit $0.34 on May 18, after which it went on a tear and rose to $0.53 three days later. Since then, it's whipsawed a bit. Comment! [Healthcare, On the Move]
Tuesday, March 20, 2012, 8:12 AM BioSante Pharmaceuticals (BPAX) announces positive results from studies of its Pill-Plus oral contraceptive. The company is line to receive royalty payments on sales of Pill-Plus if it's eventually introduced in the U.S. Shares +14.1% premarket. Comment! [On the Move, Healthcare]
Monday, March 5, 2012, 9:06 AM Biotech analyst Adam Feurstein weighs in on the 10.5% premarket run in shares of BioSante Pharmaceuticals (BPAX) tied to the firm's announcement on its GVAX vaccine - calling out that the firm is "hyping" previously released data. 3 Comments [Healthcare, On the Move]
Monday, March 5, 2012, 8:39 AM BioSante Pharmaceuticals (BPAX) announces positive Phase 1 results from a clinical study of its GVAX prostate cancer vaccine, with an indication patients responded favorably to the treatment. Shares +7.8% premarket. Comment! [Healthcare, On the Move]
Monday, February 27, 2012, 1:16 PM Biotech analyst Adam Feuerstein doesn't pull any punches as he takes in with a jaundiced eye the 26.4% runup in shares of BioSante Pharmaceuticals (BPAX) off of its announcement of a positive test for its Pancreas cancer vaccine. "BPAX is a total failure at drug development but does a superb job writing fantastically promotional PR headlines." 1 Comment [Healthcare, On the Move]
Monday, February 27, 2012, 8:01 AM BioSante Pharmaceuticals (BPAX) announces positive results from a clinical study of its Pancreas cancer vaccine indicating that the treatment increases the median survival rate for patients. Shares of BPAX +22.3% premarket. 1 Comment [Healthcare, On the Move]
Thursday, February 16, 2012, 12:29 PM The rise in BioSante Pharmaceuticals (BPAX -13.2%) is attributable to frenzied day trading of a new momo favorite, according to biotech analyst Adam Feuerstein. He also remains underwhelmed with the FDA approval the company landed for its testosterone-boosting gel given that 5 competing products are already in the market. Despite today's selloff, BPAX is on a +67.6% YTD bender. Comment! [Healthcare, On the Move, Quick Ideas]
Wednesday, February 15, 2012, 9:05 AM Premarket gainers: BPAX +51%. IPAS +21%. BCRX +14%. WCG +11%. TSEM +9%. CMCSK +8%. EGLE +7%. CLWR +7%. CMCSA +6%. ANF +6%. HIG +6%. VTG +5%. TTM +4%. K +3%. BCS +3%. DANG +3%. YGE +3%. DMND +3%. MET +3%. ACAS +3%. GNOM +3%. BZH +3%. COF +3%. TEVA +3%. MLU +3%.
Losers: VG -12%. NBG -9%. RENN -8%. NZGA -6%. OC -5%. FXCM -3%. ALU -3%. Comment! [On the Move]
Wednesday, February 15, 2012, 7:42 AM Shares of BioSante Pharmaceuticals (BPAX) continue to rocket up after word leaked out last night that the firm landed FDA approval for its testosterone replacement gel. BPAX +66.2% premarket, partner TEVA +3.1%. Comment! [On the Move, Healthcare]
Tuesday, February 14, 2012, 5:04 PM BioSante Pharmaceuticals (BPAX) jumps 22.2% AH after Bloomberg reports the FDA has approved the company's Bio-T Gel, which BioSante has licensed to Teva Pharmaceuticals (TEVA). BioSante shares have been extremely volatile in recent months on account of drug-related news. Comment! [Healthcare, On the Move]

Vash Patel
$ZIP, $NOV, $BPAX, $SKUL, and $TRLG could be ready to move up, is it time to buy? http://bit.ly/Y7ZsnP
12/24/12
Reply (1)

• !Report Abuse
View all 1 replies
jamesinvest: i like $SKUL, enjoy their products, good price points, and they were everywhere you shopped for christmas.
12/24/12
• !Report Abuse
Add a reply...

140 characters

Asif Suria
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Merger Agreement $BPAX http://bit.ly/RfEL7s
10/4/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Victoria70
$BPAX is still dropping any news on its Libigel? What is going on with this company get your act together.
8/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Adam Gefvert
So BPAX is going to get a drug approved that works as well as a placebo? Maybe a placebo is what women need to feel horny.
6/14/12
Reply (6)

• !Report Abuse
View all 6 replies
Victoria70: so are we getting approval or not? I think its great news .....
6/14/12
• !Report Abuse
Frank Petry: Actually, Palatins Bremelanotide is more like Viagra than Libigel. Libigel is long term treatment where as Brem is a fast acting compound
9/14/12
• !Report Abuse
Add a reply...

140 characters

Victoria70
gm traders: Is there any news on BPAX?
6/11/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Victoria70
Good evening Traders: Any good news on $BPAX would love to hear it considering we had such a bad streak the past week. Thanks
6/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/MDGnK6 After hours big gainer: $ACOM, $ACHN, $NBIX, $HNSN, $YRCW, $BPAX, $IRM, $KBH, $AES, $CX
6/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ron Reed
BPAX Reverse stock split announced. 1:6 end of today 6-1-12. You heard it here first...
6/1/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Victoria70
$KERX is making a move now! So, is $BPAX up from .34 closed around .53. Any advice on these two stock would be greatly appreciated. Thanks
5/21/12
Reply (5)

• !Report Abuse
View all 5 replies
iadops40: rule no. 1 ...don't get greedy with biotech, take profits
5/21/12
• !Report Abuse
iadops40: analyst sentiment is a 4 target with a high target of 7
5/21/12
• !Report Abuse
Add a reply...

140 characters

mtsjake
Will TEVA every buyout BPAX?
4/30/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Vash Patel
$ZIP, $NOV, $BPAX, $SKUL, and $TRLG could be ready to move up, is it time to buy? http://bit.ly/Y7ZsnP
12/24/12
Reply (1)

• !Report Abuse
View all 1 replies
jamesinvest: i like $SKUL, enjoy their products, good price points, and they were everywhere you shopped for christmas.
12/24/12
• !Report Abuse
Add a reply...

140 characters

Adam Gefvert
So BPAX is going to get a drug approved that works as well as a placebo? Maybe a placebo is what women need to feel horny.
6/14/12
Reply (6)

• !Report Abuse
View all 6 replies
Victoria70: so are we getting approval or not? I think its great news .....
6/14/12
• !Report Abuse
Frank Petry: Actually, Palatins Bremelanotide is more like Viagra than Libigel. Libigel is long term treatment where as Brem is a fast acting compound
9/14/12
• !Report Abuse
Add a reply...

140 characters

Victoria70
$KERX is making a move now! So, is $BPAX up from .34 closed around .53. Any advice on these two stock would be greatly appreciated. Thanks
5/21/12
Reply (5)

• !Report Abuse
View all 5 replies
iadops40: rule no. 1 ...don't get greedy with biotech, take profits
5/21/12
• !Report Abuse
iadops40: analyst sentiment is a 4 target with a high target of 7
5/21/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
LOL! I am lucky! Someone asked me the other day about biotechs under $3 and I said to look into BPAX & KVPBQ.PK, which ended today up 41% & 11%.
2/6/12
Reply (11)

• !Report Abuse
View all 11 replies
Michael Bryant: Um............my profile said I graduated. And didn't I disclose how much I make a few weeks ago. Prove me wrong.
2/6/12
• !Report Abuse
AlphaVolume: ADVISOR....
2/6/12
• !Report Abuse
Add a reply...

140 characters

Jonathan Spencer
Who has $CTIC and $BPAX? Updates might be coming
1/9/12
Reply (1)

• !Report Abuse
View all 1 replies
John Rayhall: Don't have BPAX but have ATRS and CLDX sold INHX today.
1/9/12
• !Report Abuse
Add a reply...

140 characters

BPAX Biosante Pharmaceuticals, Inc.

BPAX

Biosante Pharmaceuticals, Inc.